Jyong Biotech Ltd. (MENS)
NASDAQ: MENS · Real-Time Price · USD
2.064
+0.004 (0.19%)
Oct 8, 2026, 1:55 PM EDT - Market open
Jyong Biotech Earnings Call Transcripts
Fiscal Year 2026
-
MCS-2 is highlighted for its unique action and safety in treating benign prostatic hyperplasia, with the company among the first to secure FDA phase III approval for a botanical drug, positioning it for early market entry.